Ipilimumab and nivolumab plus focused liver radiation for locally advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, open-label interventional study combines two immune checkpoint inhibitors—nivolumab and ipilimumab—with stereotactic body radiotherapy (SBRT) to treat adults with locally advanced or borderline resectable hepatocellular carcinoma. Participants must have measurable liver tumors without extrahepatic spread and meet criteria including ECOG 0–1 and adequate organ and marrow function. The primary focus is safety and tolerability of the combination and determining a recommended dose and schedule, with secondary observation of tumor response by RECIST 1.1 and local control after SBRT. Enrollment is conducted at The Queen's Medical Center and the University of Hawai'i Cancer Center with emphasis on including Native Hawaiian and Pacific Islander patients to address local disparities.

Why it matters

Who can join: the full rules

Main Criteria for Inclusion/Exclusion

* Inclusion Criteria:

  * Histologically or cytologically confirmed hepatocellular cancer
  * Locally advanced/borderline resectable HCC as defined by:

    * Solitary tumor \>5 cm, OR
    * Unilobar multifocal disease either with \>3 tumors or one tumor \>3 cm, OR
    * Bilobar disease with adequate future liver remnant, still technically resectable, OR
    * High risk disease features (tumor \>3 cm with macrovascular invasion or tumor \>3 cm with AFP\>400).
  * No extrahepatic spread, no nodal disease, no bilateral left and right branch portal vein involvement, no hepatic vein / IVC involvement. Unilateral hepatic vein involvement is not exclusionary.
  * Measurable disease per RECIST 1.1 as determined by the investigator
  * Age ≥ 18 years old on the day of consent
  * ECOG performance status ≤1 (Appendix XX)
  * Adequate organ and marrow function, as defined below. Criteria "a," "b," "c," and "f" cannot be met with transfusions, infusions, or growth factor support administered within 14 days of starting the first dose.

    * Hemoglobin ≥9 g/dL
    * Absolute neutrophil count ≥1000/μL
    * Platelet count ≥90,000/μL
    * Total bilirubin (TBL) \<2.0 mg/dL
    * ASTandALT≤5×ULN
    * Albumin≥2.8g/dL
    * International normalized ratio(INR)≤2xULN
    * Calculated creatinine clearance ≥ 40 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance
* Exclusion Criteria:

  * Prior systemic therapy for hepatocellular carcinoma
  * Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of study drug(s).
  * Ascites that requires ongoing paracentesis, within 6 weeks prior to the first scheduled dose, to control symptoms.
  * Active or prior documented GI variceal bleed or history of upper GI bleeding, ulcers, or esophageal varices with bleeding within 60 days prior to registration; adequate endoscopic therapy according to institutional standards is required for patients with history of esophageal variceal bleeding or assessed as high risk for esophageal variceal by the treating investigator.
  * Hepatic encephalopathy within 12 months of trial registration
  * Patient currently exhibits symptomatic or uncontrolled hypertension defined as diastolic blood pressure \>90 mmHg or systolic blood pressure \>140 mmHg.
  * Prior external beam radiation therapy to the liver, prior yttrium-90 radioembolization
  * HBV viral load \>100 IU/mL, ongoing corticosteroid therapy \>10 mg prednisone daily, and active autoimmune disease requiring systemic therapy in the past 2 years.
  * Direct tumor extension into stomach, duodenum, small or large bowel
  * Active or untreated central nervous system (CNS) and leptomeningeal metastases
  * History of another primary malignancy except for:

    * Malignancy treated with curative intentand with no known active disease ≥ 5years before the first dose of study drug(s) and of low potential risk for recurrence
    * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    * Adequately treated carcinoma in situ without evidence of disease
  * Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  * Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), or human immunodeficiency virus (positive human HIV 1/2 antibodies).

Where it's running

• The Queen's Medical Center
  Honolulu, Hawaii, United States Recruiting
• University of Hawai'i Cancer Center
  Honolulu, Hawaii, United States Not yet recruiting

Study contacts

• Principal investigator: Jared D Acoba, MD — University of Hawaii
• Study coordinator: Jared D Acoba, MD
• Email: jacoba@hawaii.edu
• Phone: 8085318521

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• 30-minute cycling immediately before nivolumab and ipilimumab for metastatic melanoma

  This trial will test whether a 30-minute cycling session immediately before nivolumab plus ipilimumab boosts immune activity and improves outcomes for people with metastatic melanoma.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07564570

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.